Robert M Cronin1,2,3, Tim Lucas Dorner4, Amol Utrankar5, Whitney Allen6, Mark Rodeghier7, Adetola A Kassim8, Gretchen Purcell Jackson1,2,9, Michael R DeBaun10. 1. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 4. Berner Fachhochschule, Biel, Switzerland. 5. School of Medicine, Vanderbilt University, Nashville, Tennessee. 6. School of Medicine, Meharry Medical College, Nashville, Tennessee. 7. Rodeghier Consultants, Chicago, Illinois. 8. Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee. 9. Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. 10. Division of Hematology/Oncology, Department of Pediatrics, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
OBJECTIVE: Recurrent vaso-occlusive pain episodes, the most common complication of sickle cell disease (SCD), cause frequent health care utilization. Studies exploring associations between patient activation and acute health care utilization for pain are lacking. We tested the hypothesis that increased activation and self-efficacy are associated with decreased health care utilization for pain in SCD. METHODS: In this cross-sectional study of adults with SCD at a tertiary medical center, we collected demographics, SCD phenotype, Patient Activation Measure levels, and self-efficacy scores using structured questionnaires. We reviewed charts to obtain disease-modifying therapy and acute health care utilization, defined as emergency room visits and hospitalizations, for vaso-occlusive pain episodes. Negative binomial regression analyses were used to test the hypothesis. RESULTS: We surveyed 67 adults with SCD. The median age was 27.0 years, 53.7% were female, and 95.5% were African American. Median health care utilization for pain over one year (range) was 2.0 (0-24). Only one-third of participants (38.8%) were at the highest activation level (median [range] = 3 [1-4]). Two-thirds (65.7%) of participants had high self-efficacy (median [range] = 32.0 [13-45]). Regressions showed significant association between health care utilization and activation (incidence rate ratio [IRR] = 0.663, P = 0.045), self-efficacy (IRR = 0.947, P = 0.038), and male sex (IRR = 0.390, P = 0.003). Two outliers with high activation, self-efficacy, and health care utilization also had addictive behavior. CONCLUSIONS: Many individuals with SCD have suboptimal activation and reduced self-efficacy. Higher activation and self-efficacy were associated with lower health care utilization for pain. Additional studies are needed to evaluate interventions to improve activation and self-efficacy and reduce acute health care utilization for pain.
OBJECTIVE: Recurrent vaso-occlusive pain episodes, the most common complication of sickle cell disease (SCD), cause frequent health care utilization. Studies exploring associations between patient activation and acute health care utilization for pain are lacking. We tested the hypothesis that increased activation and self-efficacy are associated with decreased health care utilization for pain in SCD. METHODS: In this cross-sectional study of adults with SCD at a tertiary medical center, we collected demographics, SCD phenotype, Patient Activation Measure levels, and self-efficacy scores using structured questionnaires. We reviewed charts to obtain disease-modifying therapy and acute health care utilization, defined as emergency room visits and hospitalizations, for vaso-occlusive pain episodes. Negative binomial regression analyses were used to test the hypothesis. RESULTS: We surveyed 67 adults with SCD. The median age was 27.0 years, 53.7% were female, and 95.5% were African American. Median health care utilization for pain over one year (range) was 2.0 (0-24). Only one-third of participants (38.8%) were at the highest activation level (median [range] = 3 [1-4]). Two-thirds (65.7%) of participants had high self-efficacy (median [range] = 32.0 [13-45]). Regressions showed significant association between health care utilization and activation (incidence rate ratio [IRR] = 0.663, P = 0.045), self-efficacy (IRR = 0.947, P = 0.038), and male sex (IRR = 0.390, P = 0.003). Two outliers with high activation, self-efficacy, and health care utilization also had addictive behavior. CONCLUSIONS: Many individuals with SCD have suboptimal activation and reduced self-efficacy. Higher activation and self-efficacy were associated with lower health care utilization for pain. Additional studies are needed to evaluate interventions to improve activation and self-efficacy and reduce acute health care utilization for pain.
Authors: Max A Brodsky; Mark Rodeghier; Maureen Sanger; Jeannie Byrd; Brandi McClain; Brittany Covert; Dionna O Roberts; Karina Wilkerson; Michael R DeBaun; Adetola A Kassim Journal: Am J Med Date: 2017-01-05 Impact factor: 4.965
Authors: John Andrawis; Sina Akhavan; Vanessa Chan; Mandeep Lehil; Dana Pong; Kevin J Bozic Journal: Clin Orthop Relat Res Date: 2015-03-11 Impact factor: 4.176
Authors: Edward Zimbudzi; Clement Lo; Sanjeeva Ranasinha; Gregory R Fulcher; Stephen Jan; Peter G Kerr; Kevan R Polkinghorne; Grant Russell; Rowan G Walker; Sophia Zoungas Journal: BMJ Open Date: 2017-10-22 Impact factor: 2.692
Authors: Ronald W Gimbel; Lior M Rennert; Paul Crawford; Jeanette R Little; Khoa Truong; Joel E Williams; Sarah F Griffin; Lu Shi; Liwei Chen; LingLing Zhang; Jennie B Moss; Robert C Marshall; Karen W Edwards; Kristy J Crawford; Marie Hing; Amanda Schmeltz; Brandon Lumsden; Morgan Ashby; Elizabeth Haas; Kelly Palazzo Journal: J Med Internet Res Date: 2020-05-26 Impact factor: 5.428
Authors: V Shane Pankratz; E Eunice Choi; Fares Qeadan; Donica Ghahate; Jeanette Bobelu; Robert G Nelson; Thomas Faber; Vallabh O Shah Journal: J Diabetes Complications Date: 2020-10-09 Impact factor: 2.852